Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia
Monica Kasbekar, Valentina Nardi, Paola Dal Cin, Andrew M. Brunner, Meghan Burke, Yi‐Bin Chen, Christine Connolly, Amir T. Fathi, Julia Foster, Molly Macrae, Steven L. McAfee, Kristin McGregor, Rupa Narayan, Aura Y. Ramos, Tina T. Som, Meghan Vartanian, Robb S. Friedman, Karim A. Benhadji, Gabriela Hobbs
Abstract
Key Points A novel PCM1-FGFR1 gene rearrangement was identified in a patient with a myeloid neoplasm with eosinophilia. Futibatinib, an oral selective small molecule inhibitor of FGFR1-4, resulted in a durable complete hematologic and cytogenetic remission.
Topics & Concepts
Fibroblast growth factor receptor 1EosinophiliaNeoplasmMyeloid leukemiaComplete remissionMyeloidMedicineCancer researchInternal medicineOncologyFibroblast growth factorChemotherapyPathologyReceptorEosinophilic Disorders and SyndromesInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisMyeloproliferative Neoplasms: Diagnosis and Treatment